Practical Guidance for YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol in Research Workflows

What This Product Solves

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, available as YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol from APExBIO (SKU B7641), is a crystalline small molecule sGC activator and post-transcriptional inhibitor of hypoxia-inducible factor-1α (HIF-1α). Its primary utility is in dissecting the molecular mechanisms of hypoxia signaling, tumor angiogenesis inhibition, and apoptosis within cancer biology research. YC-1 enables precise suppression of HIF-1α transcriptional activity in cell-based and animal models, supporting studies on tumor growth and vascularization under hypoxic conditions. Researchers commonly leverage this compound to clarify HIF-1-driven pathways, particularly in hepatoma and other solid tumor models, where hypoxia is a critical determinant of disease progression. YC-1 should not be used for human or veterinary diagnostic or therapeutic purposes.

In the internal article "Harnessing YC-1 in Hypoxia and Cancer Assays: Protocols & Insights", the application of YC-1 in hypoxia signaling and tumor angiogenesis studies is described in detail, including actionable strategies for maximizing experimental reproducibility. For experimental optimization and troubleshooting in cell-based assays, see "Optimizing Cell-Based Assays with YC-1 (5-(1-benzyl-1H-in...".

Protocol Parameters

• Compound Solubility | ≥30.4 mg/mL in DMSO; ≥16.2 mg/mL in ethanol | Recommended for formulation of stock solutions before dilution into cell culture or animal dosing buffers | DMSO and ethanol provide sufficient solubility for preparing concentrated stocks, minimizing vehicle volume in biological assays | product dossier
• Storage Conditions | Room temperature for solid; avoid long-term storage of solutions | Ensures compound stability prior to reconstitution; freshly prepare solutions for each experiment | YC-1 is stable as a powder at ambient temperature but degrades in solution, so solutions should be used promptly | product dossier
• Working Concentration Range | 1–50 µM (typical for in vitro cell-based assays) | Supports inhibition of hypoxia-inducible factor 1 transcriptional activity in cancer research | Empirical range commonly used for HIF-1α inhibition and tumor angiogenesis inhibition, though precise values should be optimized for each cell line or system | workflow recommendation

Workflow Setup and QC Checklist

To maximize reproducibility and specificity when using YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol in research workflows, adhere to the following setup and quality control steps:

• Stock Solution Preparation: Dissolve YC-1 in DMSO or ethanol at recommended solubility limits. Ensure complete dissolution before sterile filtration. Avoid water, as YC-1 is insoluble.
• Aliquoting and Storage: Prepare single-use aliquots to avoid freeze-thaw cycles. Store solid compound at room temperature; discard unused solutions after each experiment.
• Vehicle Controls: Include matched DMSO/ethanol vehicle controls in all experimental arms to account for solvent effects on cell viability or assay readouts.
• Concentration Titration: Empirically determine optimal working concentrations for each cell line or animal model. Begin with a broad range (e.g., 1, 10, 25, 50 µM) and monitor for cytotoxicity and target pathway modulation.
• Assay-Specific QC: When studying inhibition of hypoxia-inducible factor 1 transcriptional activity, confirm HIF-1α protein levels and downstream gene expression changes using western blotting or qRT-PCR.
• Batch Documentation: Record lot number, date of preparation, and storage conditions for each batch to ensure traceability and troubleshooting capability.

Common Failure Modes and Fixes

• Incomplete Dissolution: If YC-1 does not fully dissolve at the recommended solubility, gently warm the solution to 37°C and vortex. If insolubility persists, verify solvent quality and avoid exceeding the solubility threshold.
• Loss of Activity in Solution: Degradation can occur if solutions are stored too long; always prepare fresh working solutions immediately prior to use and avoid exposure to light and moisture.
• Unintended Cytotoxicity: If non-specific cytotoxic effects are observed, titrate down the concentration and verify vehicle-only controls for baseline toxicity.
• Variable Assay Readouts: Ensure consistent cell density, passage number, and environmental parameters (e.g., oxygen levels in hypoxia assays) for each experimental repeat.
• Solvent Interference: Keep final DMSO/ethanol concentration in cell culture below 0.1%–0.5% to minimize off-target effects.

Scope and Limitations

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is suitable for applications requiring inhibition of hypoxia-inducible factor 1 transcriptional activity, tumor angiogenesis inhibition, and apoptosis and cancer biology research in vitro and in vivo. The compound is not water-soluble and is intended exclusively for laboratory research use, not for clinical, diagnostic, or therapeutic deployment. Experimental use should comply with established protocols for sGC activators and HIF-1α inhibitors. Researchers should note that all efficacy and specificity claims must be validated within their own assay context, as no universal cross-system effect is guaranteed.

Conclusion

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol offers a robust tool for modulating hypoxia and vascular signaling in cancer research settings. By adhering to established solubility, storage, and assay design parameters, researchers can mitigate common failure modes and enhance data reproducibility. For detailed workflow integration and advanced protocol guidance, consult the product page at APExBIO and reference peer-developed workflows in the linked articles above.